PHARMOS made a net profit of CZK 11.2 mil with revenues of CZK 10,337 mil in 2019, up by 128% and up by 1.62%, respectively, compared to the previous year. This translates into a net margin of 0.108%.
On the operating level, EBITDA reached CZK 57.5 mil, up 21.6% compared to the previous year. Over the last five years, the company's EBITDA has risen 4.91% a year on average.
The company generated cash, defined by a sum of net profit and depreciation, of CZK 30.8 mil or 0.298% of sales. When investments are excluded, free cash flow reached CZK 10.8 mil, or 0.105% of sales in 2019.
In the last five years, the company generated free cash flow of CZK 43.8 mil. That compares to a cumulative net profit of CZK 94.3 mil in the same period.
You can see all the company’s data at PHARMOS profile, or you can download a report on the company in the report section.
Helgi Library 
